Qiyu Biotech is an innovative macromolecular drug developer.
Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody technology platform to build superior biopharmaceutical pipelines and explore the field of biotherapy. A big breakthrough. With the development and improvement of the company, Qiyu will have core competitiveness in more fields.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 23, 2021 | Series B | ¥200M | 2 | — | — | Detail |
| Aug 13, 2019 | Series A | — | 2 |
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
|
Yes | Series A |
|
|
— | Series B |
Longmen Capital
|
— | Series B |